LCTX - AMEX

Lineage Cell Therapeutics, Inc.

LCTX·AMEX

$1.21

-0.83%

HealthcareBiotechnology

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$301.65M

EPS-0.2800

P/E Ratio-6.05

Earnings Date08/11/2026

112.58M

Assets

-1%

3Y-9.0%

5Y+4.0%

10Y-21.0%

69.24M

Total Liabilities

91%

3Y+34.0%

5Y+440.0%

10Y+474.0%

43.35M

Total Equity

-44%

3Y-40.0%

5Y-54.0%

10Y-67.0%

Lineage Cell Therapeutics, Inc. Funding & Solvency Profile

LCTX · AMEX

Current Assets

Cash & Cash Equivalents40.79M

Net Receivables1.56M

Inventory0.00

Other Current Assets1.81M

Total Current Assets59 M

Non-Current Assets

Property, Plant & Equipment4.70M

Goodwill & Intangible Assets42.37M

Long-Term Investments0.00

Other Non-Current Assets558.00K

Total Non-Current Assets5 M

Total Assets

112.58M

Financial Health Analysis

Current Ratio

5.20x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.60x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

48 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

53% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Lineage Cell Therapeutics, Inc. Balance Sheet

LCTX • AMEX

Lineage Cell Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	40.8M	45.8M	35.4M	11.4M	55.7M	32.6M	9.5M	23.6M	36.8M	22.1M	42.2M	29.5M	5.5M	4.3M	22.2M	33.3M	12.2M	12.3K	9.5K	561K
Short-Term Investments	15M	2M	50K	46.5M	2.6M	9M	21.2M	7.2M	1.3M	627K	753K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	55.8M	47.8M	35.5M	57.9M	58.4M	41.6M	30.7M	30.7M	38.2M	22.7M	43M	29.5M	5.5M	4.3M	22.2M	33.3M	12.2M	12.3K	9.5K	561K
Net Receivables	1.6M	638K	745K	297K	50.8M	4K	24.7M	3.7M	3M	1.2M	1.6M	1M	1.1M	0.0	0.0	0.0	-138.5K	0.0	0.0	0.0
Accounts Receivables	1.6M	638K	745K	297K	50.8M	4K	1.1M	767K	780K	446K	1.1M	663.9K	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	23.6M	3M	2.3M	711K	567K	378K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1K	266K	178.7K	55.3K	51.2K	45.5K	38.4K	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	2.4M	2.4M	0.0	1.9M	1.4M	1.8M	2.6M	1.2M	1.2M	2.8M	2.7M	2.2M	138.5K	96.6K	132.1K	57.7K
Other Current Assets	1.8M	2.6M	2.2M	1.8M	0.0	0.0	2.1M	0.0	0.0	0.0	567K	380.8K	0.0	0.0	0.0	0.0	138.5K	96.6K	132.1K	0.0
Total Current Assets	59.2M	51M	38.4M	60M	111.5M	44M	57.5M	36.4M	42.6M	25.6M	47.2M	32.4M	7.9M	7.2M	25M	35.6M	12.4M	108.9K	141.6K	618.7K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	4.7M	4.4M	4.8M	5.7M	4.9M	5.6M	8.2M	5.8M	5.5M	5.5M	7.5M	2.9M	3M	1.3M	1.3M	710.8K	131.1K	105.6K	12.5K	10.8K
Goodwill	10.7M	10.7M	10.7M	10.7M	10.7M	10.7M	10.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	31.7M	46.5M	46.6M	46.7M	46.8M	47M	48.2M	3.1M	6.9M	10.2M	33.6M	38.8M	46.2M	20.5M	18.6M	15.4M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	42.4M	57.2M	57.2M	57.4M	57.5M	57.7M	58.9M	3.1M	6.9M	10.2M	33.6M	38.8M	46.2M	20.5M	18.6M	15.4M	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	581K	0.0	0.0	100K	33.7M	117.2M	100M	4.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	5.8M	0.0	0.0	-581K	0.0	0.0	0.0	22.1M	0.0	118K	322K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	558K	614K	577K	627K	630K	616K	764K	505K	1M	1M	1.3M	790.1K	574K	733.8K	907K	1.6M	935.9K	821K	21K	21K
Total Non-Current Assets	53.4M	62.2M	62.6M	63.7M	63M	64M	68M	65.3M	130.6M	116.9M	47.4M	42.5M	49.8M	22.6M	20.9M	17.7M	1.1M	926.6K	33.5K	31.8K
Total Assets	112.6M	113.2M	101M	123.7M	174.5M	107.9M	125.5M	101.7M	173.2M	142.6M	94.7M	74.9M	57.7M	29.7M	45.8M	53.3M	13.4M	1M	175.1K	650.5K
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.3M	1.2M	2.1M	2.4M	3.5M	2.6M	2.4M	2.4M	938K	1.6M	2.8M	2.3M	3.4M	1.2M	1.1M	0.0	0.0	0.0	480.4K	431.7K
Accounts Payable	2.3M	1.2M	2.1M	2.4M	3.5M	2.6M	2.4M	2.4M	938K	1.6M	2.8M	2.3M	3.4M	1.2M	1.1M	0.0	0.0	0.0	480.4K	431.7K
Accrued Expenses	0.0	4.3M	1.1M	2.4M	22.1M	1.7M	1.5M	2.5M	2.3M	1.9M	6.1M	3.1M	2.3M	2.3M	583.6K	0.0	0.0	0.0	0.0	0.0
Short Term Debt	853K	0.0	0.0	0.0	0.0	523K	1.2M	70K	152K	932K	95K	117.7K	0.0	0.0	0.0	0.0	0.0	1.9M	716.5K	0.0
Capital Lease Obligations (Current)	0.0	1.2M	882K	952K	831K	762K	0.0	237K	212K	202K	38K	58K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	3.3M	7.4M	10.8M	9.4M	18.1M	193K	45K	42K	797K	572K	3M	208.4K	235.3K	400.9K	465.5K	550.1K	367.9K	312.9K	261.1K	183.9K
Other Current Liabilities	4.8M	0.0	3.1M	3.8M	2.5M	2M	1.3M	1.6M	2.5M	3.6M	3.4M	1.3M	991.7K	497.8K	1.2M	2.2M	898.9K	1.2M	0.0	0.0
Total Current Liabilities	11.4M	14M	18M	19M	47.1M	7.8M	6.5M	6.8M	6.9M	8.9M	12.5M	7.1M	7M	4.4M	3.1M	2.5M	1.2M	3.4M	1.5M	615.6K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18K	1.2M	544K	60K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	14.4M	18.7M	27.7M	32.5M	0.0	200K	0.0	0.0	308K	615K	97.3K	0.0	768.7K	899.6K	1M	1.2M	1.5M	1.7M	0.0
Deferred Tax Liabilities (Non-Current)	22K	273K	273K	2.1M	2.1M	2.1M	3.3M	0.0	0.0	50K	158K	4.5M	8.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	56.3M	6.2M	0.0	2K	30K	437K	277K	644K	930K	58K	166K	65.5K	232K	294.7K	325.3K	318.3K	0.0	483.7K	22.8K	1.9M
Total Non-Current Liabilities	57.9M	22.2M	21M	32.7M	36.5M	5.1M	7.7M	2.6M	2.1M	3.2M	5.8M	5M	8.5M	1.1M	1.2M	1.4M	1.2M	2M	1.8M	1.9M
Capital Lease Obligations	1.6M	2.5M	3M	3.9M	2.8M	3.3M	3.9M	2.2M	1.4M	1.9M	4.5M	466.8K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	69.2M	36.2M	39M	51.7M	83.6M	12.8M	14.2M	9.4M	9M	12.1M	18.2M	12.2M	15.5M	5.5M	4.4M	3.8M	2.4M	5.4M	3.2M	2.5M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.9M	-18M	-19.9M	-43M	-8.4M	-6M	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	515.5M	484.7M	451.3M	440.3M	434.5M	393.9M	387.1M	354.3M	378.5M	317.9M	274.3M	234.8M	203.5M	119.8M	115.1M	101.1M	59.7M	43.2M	40.7M	0.0
Additional Paid-In Capital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	378.5M	0.0	0.0	234.9M	94K	94K	94K	94K	94K	94K	94K	40.5M
Retained Earnings	-467M	-403.5M	-384.9M	-363.4M	-337.1M	-294.1M	-273.4M	-261.9M	-216.3M	-196.3M	-229.2M	-182.2M	-145.8M	-101.9M	-80.5M	-64M	-52.8M	-47.6M	-43.8M	-42.4M
Accumulated Other Comprehensive Income/Loss	-3.9M	-2.9M	-3.1M	-3.6M	-5.2M	-3.7M	-681K	1.4M	451K	-738K	-237K	185.8K	62.9K	-59.6K	-122.7K	897.3K	-54.3K	-602.5K	-585.8K	-580.9K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-378.5M	0.0	0.0	-469.7M	0.0	0.0	0.0	0.0	0.0	602.5K	585.8K	580.9K
Total Stockholders' Equity	44.5M	78.4M	63.4M	73.3M	92.2M	96.2M	113M	93.8M	162.6M	117.9M	26.9M	36.5M	14.8M	9.6M	28.6M	38.2M	7M	-4.3M	-3M	-1.9M
Total Equity	43.3M	77M	62M	71.9M	90.9M	95.1M	111.2M	92.2M	164.3M	130.5M	76.4M	62.7M	42.3M	24.3M	41.5M	49.4M	11M	-4.3M	-3M	-1.9M
Minority Interest	-1.2M	-1.4M	-1.4M	-1.4M	-1.3M	-1.1M	-1.7M	-1.6M	1.6M	12.6M	49.6M	26.3M	27.5M	14.7M	12.8M	11.3M	4M	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	112.6M	113.2M	101M	123.7M	174.5M	107.9M	125.5M	101.7M	173.2M	142.6M	94.7M	74.9M	57.7M	29.7M	45.8M	53.3M	13.4M	1M	175.1K	650.5K
Total Investments	15M	2M	50K	47.1M	2.6M	9M	21.3M	40.9M	118.5M	100.7M	5.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	2.4M	2.5M	3M	3.9M	2.8M	3.8M	5.2M	2.3M	1.5M	4M	5.1M	527K	0.0	0.0	0.0	0.0	0.0	1.9M	716.5K	0.0
Net Debt	-38.4M	-43.3M	-32.5M	-7.5M	-52.9M	-28.8M	-4.3M	-21.3M	-35.3M	-18.1M	-37.1M	-29M	-5.5M	-4.3M	-22.2M	-33.3M	-12.2M	1.9M	707K	-561K
Shares Outstanding	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090	230,034,090

SEC Filings

LCTX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
S-3 S-3 N/A	March 11, 2026	March 11, 2026		View Filing
8-K 8-K 2026 N/A	March 11, 2026	March 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 28, 2025	November 28, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 24, 2025	November 20, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing

Showing 1 to 10 of 706 filings

Related Guides

Blog Categories

Continue your LCTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.